According to previous reports, the following questions remain to be resolved [38]: First, it will be important to identify the subsets of patients with DCM that will benefit the most from IA therapy, or determine whether patients with elevated levels of circulating autoantibodies (e.g., anti-β1-AR autoantibodies) should be studied. The gene discussed is ADRB1; the disease is familial dilated cardiomyopathy.